Current Induction Therapy Strategies and Anti-T Lymphocyte Globulin Usage in Kidney Transplantation: Consensus-Based Recommendations by a Turkish Expert Panel

This advisory committee convened to review national and global kidney transplantation dynamics and provide recommendations on the use of anti-T lymphocyte globulin (ATLG) for prevention and treatment of rejection afer allogeneic kidney transplantation. A critical evaluation of 6 relevant articles released up to October 2022 was performed to reveal their importance in clinical practice. Additionally, 27 key questions on the indication, dosage of ATLG, and risk stratifcation were used for the Delphi technique with 8 members of the Turkish Society of Nephrology including 5 kidney transplantation (KTx) subcommittee members and a surgeon experienced in solid organ transplantation. The committee declared that Türkiye had great potential in KTx; however, increase in transplantation would be possible in the case of raise in the deceased donor transplantation. As a consensus, ATLG was strongly recommended for induction and rejection treatment. Also, committee members recommended the safe dosage range in steroid resistant acute rejection as 2.5-3 mg/kg daily for 5-7 days, and the median of preferred dosage in induction sounded as 2-2.5 mg/kg daily for 3 days in intermediate risk state. Additionally, post-transplant infection and malignancy cases due to immunosuppression were much rarely encountered than they were in the past.

Cite this article as: Çakır Ü, Dinçkan A, Karadoğan N, et al. Current induction therapy strategies and ATLG usage in kidney transplantation: Consensus-based recommendations by a Turkish expert panel. Turk J Nephrol. 2024;33(2):145-152.